Bacteriophages Market Is Anticipated To Reach US$ 72.1 Million By 2032

The population's changing and hurried lifestyles are to blame for the increase in the frequency of gastrointestinal complaints. The preservation of good stomach bacteria by bacteriophages is known to improve digestion, maintain regular bowel motions, and lessen intestinal inflammation. Customers therefore readily accept Bacteriophage as pre/probiotic dietary supplements.

Users who have bacterial infections have been in great demand for Bacteriophage. Producing bacteriophage dietary supplements for a healthy gut has helped major industry players maintain a dominant position in the healthcare market. The usage of bacteriophage therapy among patients has been greatly influenced by rising rates of dysentery and UTIs.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 : https://www.factmr.com/connectus/sample?flag=S&rep_id=5558?PJ

From 2017 to 2021, end users used phage probiotics at a compound annual growth rate of 3.5%.

𝐊𝐞𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐏𝐫𝐨𝐟𝐢𝐥𝐞𝐝

• Life Extension
• Arthur Andrew Medical
• ADM.
• Biochimpharm
• Micreos Human Health
• Designs for Health
• Armata Pharmaceuticals Inc.
• The biostation
• Probiotic America
• Microgen

By 2032, the European bacteriophage market is anticipated to generate US$28.5 million.
Demand for preventative healthcare has increased as consumers' preferences for a healthy lifestyle have changed. Additionally, it has inspired manufacturers to create new, useful goods that support healthy lifestyle maintenance in a variety of ways in response to customer demands. Consequently, the bacteriophage sector gains access to a big market.

The research also includes profiles of the Bacteriophage industry's goods, sales, returns, competitive landscape, market structure, industry drivers, and key business challenges. The study calculates the market's current growth rate, projected future growth, and the key drivers that will affect that growth in 2022. The research also anticipates sales for the years 2022 to 2032

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

Prominent bacteriophage manufacturers are Life Extension, Arthur Andrew Medical, ADM, Biochimpharm, Micreos Human Health, and Probiotic America.

Rising prevalence of antibiotic resistance and limited discoveries of new antibiotics in the market are major factors compelling key market players to develop bacteriophage therapy products. Manufacturers are extending their consumer reach with mergers and partnerships. Robust R&D and new product launches that address the existing concerns of end users are being witnessed in this space.

• In Nov 2021, ADM acquired U.S.-based Deerland Probiotics and Enzymes, which specializes in developing dietary supplements that benefit human microbe health.

• In August 2021, Intralytix was awarded a Fast Track NIH SBIR contract to create a global scale-independent AI-based platform for producing high titer bacteriophage preparations for clinical applications.

Fact.MR has provided detailed information about the price points of key manufacturers of bacteriophages positioned across regions, sales growth, production capacity, and speculative technological expansion, in the recently published report.

𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐁𝐚𝐜𝐭𝐞𝐫𝐢𝐨𝐩𝐡𝐚𝐠𝐞 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡

• By Product Type :

• Phage Probiotics
• Phage Therapeutics
• By Route of Administration :
• Oral
• Topical
• Others

• By Application :

• Gastroenterology
• Respiratory Infections Treatment
• Skin Infection Treatment
• Wound Prophylaxis
• Urogenital Infection Treatment
• Others

• By Distribution channel :

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

• By Region :

• North America
• Latin America
• Europe
• East Asia
• South Asia & Oceania
• MEA

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:https://www.factmr.com/connectus/sample?flag=RC&rep_id=5558?PJ

US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E Mail : sales@factmr.com

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.

This release was published on openPR.